Navigation Links
Reported Use of AMAG's Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are 'On the Verge' of Use
Date:11/23/2009

EXTON, Pa., Nov. 23 /PRNewswire/ -- BioTrends Research Group, Inc. released Wave 2 of its LaunchTrends(TM): Feraheme report, the second in a multi-phase syndicated market research project tracking the launch of AMAG's new IV iron product, Feraheme, through the first six months of product availability. Each wave of the report provides quantitative information from 50 unique Nephrologists and qualitative information from a subset of 15. The reports assess trial and use of Feraheme, obstacles to use, reasons to use, typical patient types, product perceptions, promotional efforts/messages, and satisfaction with the product relative to other agents.

While only 8% of Nephrologists report use of Feraheme in chronic kidney disease - non dialysis (CKD-ND) patients and only 4% and 0% report use in peritoneal dialysis (PD) and hemodialysis (HD) patients, respectively, there are a number of Nephrologists "on the verge" of use. Two of the Nephrologists in this study reported that their dialysis units now have a contract with AMAG and they are getting ready to start using Feraheme; others report their dialysis units are considering using the product. A few Nephrologists reported that their offices have just placed orders for Feraheme and they are getting ready to try the product; others are in the midst of researching the economics and deciding whether or not it makes sense to stock Feraheme.

Among those who have used Feraheme, initial impressions are positive, although preliminary. Many have not seen follow up lab results so cannot speak to the efficacy of the product. While most have had positive experiences from a safety perspective, there are some who report concern with the product due to its newness and to some, the large doses and speed of injection present some additional reason for concern. The Nephrology practices that are using Feraheme include both offices that previously did not stock any IV iron as well as those who had been stocking Venofer and/or Ferrlecit. In addition to impacting other IV iron products, Nephrologists expect Feraheme will increase their overall use of IV iron and reduce their use of ESAs. The desire to reduce use of ESAs is particularly high with the recent release of TREAT and the advent of bundling. The next wave of research will be conducted in January at six months post launch.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

CONTACT: Jennifer Robinson of BioTrends Research Group, Inc., +1-610-363-3872, jrobinson@bio-trends.com

SOURCE BioTrends Research Group, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Shows Concord Grape Juice has a Heart-Healthy Effect not yet Reported With Red Wine
2. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
3. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
4. RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial
5. Supportive Oncology Services Accrues One Million Cancer Patient Self-Reported Assessments
6. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
7. Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
8. Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay
9. Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series
10. Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
11. Blue Light Destroys Antibiotic-Resistant Staph Infection - Results Reported in Photomedicine and Laser Surgery Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
Breaking Medicine News(10 mins):